291 Views | 499 Downloads
Address for correspondence: Scott K. Fridkin, Division of Healthcare Quality Promotion, Mailstop A35, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA; fax: 404-639-6458; e-mail: skf0@cdc.gov
We thank the infection-control and microbiology personnel from the participating Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project hospitals for reporting the data for this study.
This work was supported in part by grants to the Rollins School of Public Health of Emory University for Phases 2 and 3 of Project ICARE by AstraZeneca Pharmaceuticals (Wilmington, DE), Pfizer, Inc. (New York, NY), and Roche Laboratories (Nutley, NJ) as full sponsors, and Aventis Pharma (formerly Rhone-Poulenc Rorer) (Collegeville, PA), the National Foundation for Infectious Diseases (Bethesda, MD), the American Society for Health Systems Pharmacists Research and Education Foundation (Bethesda, MD), Kimberly-Clark Corporation (Roswell, GA), and Bayer Corporation, Pharmaceuticals Division (West Haven, CT) as partial sponsors.
Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention